Release Date:9/14/2022 1:24:00 AM

The mechanism of action of eprenetapopt (APR-246, PRIMA-1MET) as an anticancer agent remains unresolved, although the clinical development of eprenetapopt focuses on its reported mechanism of action as a mutant-p53 reactivator. Using unbiased approaches, this study demonstrates that eprenetapopt depletes cellular antioxidant glutathione levels by increasing its turnover, triggering a nonapoptotic, iron-dependent form of cell death known as ferroptosis. Deficiency in genes responsible for supplying cancer cells with the substrates for de novo glutathione synthesis (SLC7A11, SHMT2, and MTHFD1L), as well as the enzymes required to synthesize glutathione (GCLC and GCLM), augments the activity of eprenetapopt. Eprenetapopt also inhibits iron-sulfur cluster biogenesis by limiting the cysteine desulfurase activity of NFS1, which potentiates ferroptosis and may restrict cellular proliferation. The combination of eprenetapopt with dietary serine and glycine restriction synergizes to inhibit esophageal xenograft tumor growth. These findings reframe the canonical view of eprenetapopt from a mutant-p53 reactivator to a ferroptosis inducer.


Congratulations to Professor Nicholas J Clemons and co-authors from The University of Melbourne, Monash University (Australia), and Memorial Sloan Kettering Cancer Center (USA) for their excellent work published in Science Adv!




InvivoChem is proud to provide Professor Nicholas J Clemons’s team with our high-quality product Eprenetapopt (APR246; PRIMA-1MET) (Cat #: V2651; CAS #: 5291-32-7, methylated derivative of PRIMA-1 and a mutant p53 reactivator) for this research.



References: Sci Adv. 2022 Sep 16;8(37):eabm9427. doi: 10.1126/sciadv.abm9427.

Prev:Bifunctional small molecules targeting PD-L1/CXCL12 as dual immunotherapy for cancer treatment [Signal Transduct Target Ther(STTT) (IF=39)!] by researchers from Southern Medical University (Guangzhou, China) Next:A clinically applicable integrative molecular classification of meningiomas [Nature (IF=66)!] by researchers from University of Toronto (Canada), National Cancer Institute (NCI/NIH), University Hospital Tübingen (Germany), and University of California Los Angeles (UCLA)
Contact Us Back to top